Oral IL-23 Inhibitor Shows Promise for Moderate-to-Severe Psoriasis in New Trial
JNJ-77242113, an experimental IL-23 inhibitor that can be administered orally, showed solid efficacy after 16 weeks in patients with moderate-to-severe plaque psoriasis. Researchers randomly assigned patients with psoriasis to receive placebo or JNJ-77242113 at doses of 25 mg once daily, 25 mg twice daily, 50 mg once daily, 100 mg once daily, or 100 mg twice daily for 16 weeks.